Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study

References

• Sardaro A, Ferrari C, Carbonara R, et al. Synergism between immunotherapy and radiotherapy in esophageal cancer: an overview of current knowledge and future perspectives. Cancer Biother Radiopharm. 2021;36(2):123–132. doi:10.1089/cbr.2020.3643
   PubMed Web of Science ®Google Scholar
• He F, Wang J, Liu L, et al. Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015. Cancer Med. 2021;10(5):1839–1847. doi:10.1002/cam4.3647
   PubMed Web of Science ®Google Scholar
• Yang CS, Chen XL. Research on esophageal cancer: with personal perspectives from studies in China and Kenya. Int J Cancer. 2021;149(2):264–276. doi:10.1002/ijc.33421
   PubMed Web of Science ®Google Scholar
• He S, Xu J, Liu X, Zhen Y. Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B. 2021;11(11):3379–3392. doi:10.1016/j.apsb.2021.03.008
   PubMed Web of Science ®Google Scholar
• Mahmoudian RA, Mozhgani S, Abbaszadegan MR, et al. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. J Mol Histol. 2021;52(3):597–609. doi:10.1007/s10735-021-09971-3
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419–423. doi:10.1093/jjco/hye090
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren Z, Yuan L, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res. 2016;6(10):2345–2350.
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/jco.20.01888
   PubMed Web of Science ®Google Scholar
• Lu Y, Guan L, Xu M, Wang F. The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: a systematic review and meta-analysis. Transl Oncol. 2021;14(6):101083. doi:10.1016/j.tranon.2021.101083
   PubMed Web of Science ®Google Scholar
• Jin Z, Shen J, Wang C, et al. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. Ann Transl Med. 2021;9(14):1189. doi:10.21037/atm-21-2804
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Huang J, Xiao J, Fang W, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial. Cancer Med. 2021;10(5):1681–1689. doi:10.1002/cam4.3771
   PubMed Web of Science ®Google Scholar
• Su R, Zhu J, Wu S, Luo H, He Y. Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) ratio during apatinib second-line or late-line treatment in advanced esophageal squamous cell carcinoma patients. Technol Cancer Res Treat. 2022;21:15330338211072974. doi:10.1177/15330338211072974
   Web of Science ®Google Scholar
• Song PF, Xu N, Efficacy LQ. Safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133–11143. doi:10.2147/cmar.s275624
   PubMed Web of Science ®Google Scholar
• Cheng JD, Chai LX, Zhao ZP, Hao YY, Efficacy LS. Safety of anlotinib for patients with advanced NSCLC who progressed after standard regimens and the preliminary analysis of an efficacy predictor. Cancer Manag Res. 2020;12:5641–5650. doi:10.2147/cmar.s253366
   PubMed Web of Science ®Google Scholar
• Zhang B, Qi L, Wang X, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun. 2020;40(12):711–720. doi:10.1002/cac2.12119
   PubMed Web of Science ®Google Scholar
• Yang YM, Hong P, Xu WW, He QY, Li B. Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020;5(1):229. doi:10.1038/s41392-020-00323-3
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/s1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Peng C, Cohen DJ. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opin Pharmacother. 2021;22(1):93–107. doi:10.1080/14656566.2020.1813278
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi:10.1016/s0140-6736(21)01234-4
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi:10.1001/jama.2021.12836
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi:10.1056/NEJMoa2111380
   PubMed Web of Science ®Google Scholar
• Wu D, Nie J, Dai L, et al. Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer. 2019;10(7):1590–1596. doi:10.1111/1759-7714.13120
   PubMed Web of Science ®Google Scholar
• Chu L, Chen Y, Liu Q, et al. A phase II study of apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESO-Shanghai 11). Oncologist. 2021;26(6):e925–e935. doi:10.1002/onco.13668
   PubMed Web of Science ®Google Scholar
• Zhang K, Ma X, Gao H, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study. Cancer Manag Res. 2020;12:3409–3417. doi:10.2147/cmar.s246000
   PubMed Web of Science ®Google Scholar
• Bai M, Li ZG, Ba Y. Influence of KDR genetic variation on the efficacy and safety of patients with chemotherapy refractory metastatic CRC who received apatinib treatment. Int J Gen Med. 2021;14:1041–1055. doi:10.2147/ijgm.s300968
   PubMed Web of Science ®Google Scholar
• Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–599. doi:10.1016/j.annonc.2021.02.004
   PubMed Web of Science ®Google Scholar
• Yi M, Qin S, Zhao W, et al. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol. 2018;7:1. doi:10.1186/s40164-018-0120-y
   PubMed Web of Science ®Google Scholar
• Aoki T, Kudo M, Ueshima K, et al. Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD-1/PD-L1 checkpoint blockade. Cancers. 2020;12:10. doi:10.3390/cancers12103048
   Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhao L, Cui X, et al. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy. J Adv Res. 2022;35:49–60. doi:10.1016/j.jare.2021.08.011
   PubMed Web of Science ®Google Scholar
• Lin S, Liu T, Chen J, Li G, Dang J. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: a network meta-analysis. PLoS One. 2021;16(6):e0252751. doi:10.1371/journal.pone.0252751
   PubMed Web of Science ®Google Scholar
• Jiang HT, Li W, Zhang B, Gong Q, Qie HL. Efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with non-small cell lung cancer: a real-world exploratory study. Int J Gen Med. 2021;14:7625–7637. doi:10.2147/ijgm.s334436
   PubMed Web of Science ®Google Scholar
• Gao X, Peng L, Zhang L, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. J Cancer Res Clin Oncol. 2021. doi:10.1007/s00432-021-03848-4
   Web of Science ®Google Scholar
• Li S. Anlotinib: a novel targeted drug for bone and soft tissue sarcoma. Front Oncol. 2021;11:664853. doi:10.3389/fonc.2021.664853
   PubMed Web of Science ®Google Scholar
• Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–160. doi:10.1016/j.pharmthera.2017.08.012
   PubMed Web of Science ®Google Scholar
• Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–351. doi:10.1152/ajplung.00291.2003
   PubMed Web of Science ®Google Scholar
• Song Y, Xiao J, Fang W, et al. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biol Med. 2021;18(2):562–568. doi:10.20892/j.issn.2095-3941.2020.0187
   PubMed Web of Science ®Google Scholar
• Sanidas E, Papadopoulos DP, Velliou M, et al. The role of angiogenesis inhibitors in hypertension: following “ariadne’s thread. Am J Hypertens. 2018;31(9):961–969. doi:10.1093/ajh/hpy087
   PubMed Web of Science ®Google Scholar
• Aparicio-Gallego G, Afonso-Afonso FJ, León-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs. 2011;22(1):1–8. doi:10.1097/CAD.0b013e3283403806
   PubMed Web of Science ®Google Scholar